Protia, Develops Customized Allergy Diagnostic Kit for the Middle East Area

[edaily, Yoo Jin-hee] Protia (303360), a specialized in vitro diagnostic medical device company, announced on the 22nd that it has developed a customized allergy multi-diagnosis product for the Middle East (Protia Allergy-Q 64G Inhalant panel·Protia Allergy-Q 64G Food panel).

It includes new allergens specific to the Middle East, such as camel hair and dandruff allergens and date palm allergens. It is also characterized by the application of Protia's patented technology called 'Parallel Line Array' (PLA) to load 60 types of inhalant allergens and food-type allergens each.

Allergens can vary depending on environmental and genetic factors, climate differences, cultural differences, etc. This means that there are differences in major allergens with high prevalence rates. As regional allergens actually exist, requests and demand for customized allergen tests are also increasing.

German P Company (87 types) and E Company (44 types) are currently selling Middle East-specific products. Protea plans to strengthen its competitiveness by being able to diagnose a total of 120 allergens. In addition to antigens, it will actively utilize its differentiation factors such as small sample volume and shortened testing time in its marketing.

According to the industry, the size of the allergy diagnosis market in the Middle East this year is expected to reach approximately 270 million dollars (approximately 380 billion won).

Lim Kook-Jin, CEO of Protia Inc., said, “We are developing a customized allergy diagnosis kit to help diagnose and treat specialized allergy-causing substances in each region,” adding, “In the second half of the year, we plan to introduce ‘Protea Allergy-Q 192D’ that can simultaneously test a total of 192 allergens including allergen components and drug/chemical allergens.”